Web: | mayocliniclabs.com |
---|---|
Email: | mcl@mayo.edu |
Telephone: | 800-533-1710 |
International: | +1 855-379-3115 |
Values are valid only on day of printing. |
Screening for hepatitis C in primary care settings in high-risk persons with a current or past history of illicit injection drug use or a history of receiving a blood transfusion prior to 1992
Screening for hepatitis C in primary care settings in non-high risk persons born from 1945 through 1965
Screening at least once in a lifetime for all adults greater or equal to 18 years old, except in settings where the prevalence of HCV infection is less than 0.1%
This test is not offered as a screening or confirmatory test for hepatitis C in blood or human cells/tissue donors.
This test profile is not useful for detection or diagnosis of acute hepatitis C virus (HCV), since HCV antibodies may not be detectable until after 2 months following exposure and HCV RNA testing is not performed on specimens with negative HCV antibody screening test results.
This screening test is indicated for testing asymptomatic individuals that may or may not have risk factors for a hepatitis C virus infection.
Note: In accordance with National Coverage Determination guidance, this test is indicated for asymptomatic patients born from 1945 through 1965, those with a history of injection drug use, or a history of receiving blood transfusion prior to 1992.
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
HCVQN | HCV RNA Detect/Quant, S | Yes | No |
If the hepatitis C virus (HCV) antibody screen is reactive, then HCV RNA by reverse transcription-polymerase chain reaction (RT-PCR) will be performed at an additional charge.
See Hepatitis C: Testing Algorithm for Screening and Diagnosis in Special Instructions.
Chemiluminescence Immunoassay (CIA)